id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3865-0003,FDA,FDA-2024-E-3865,"Patent Extension Application from Day One Biopharmaceuticals, Inc. (on behalf of Viracta Therapeutics, Inc.) for NDA 218033",Other,Application,2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:40Z,,0,0,090000648664423a
FDA-2024-E-3865-0001,FDA,FDA-2024-E-3865,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:20Z,,0,0,0900006486644236
FDA-2024-E-3865-0002,FDA,FDA-2024-E-3865,"Patent Extension Application from Day One Biopharmaceuticals, Inc. (on behalf of Viracta Therapeutics, Inc.)  for NDA 217700",Other,Application,2024-08-19T04:00:00Z,2024,8,2024-08-19T04:00:00Z,,2024-08-19T12:31:30Z,,0,0,0900006486644238